The landscape of personalised medicine in the HR+ MBC space is constantly changing. Great summary at #ESMOAsia of how we incorporate biomarkers into our treatment sequencing.

Kicking off #ESMOAsia with a great session on precision medicine.

So many potential benefits of oral over IV PD-L1 agents… most of all economic costs + patient QoL. Could this be the future?

This is accurate

Only 3 weeks to #SABCS24, a meeting that promises to significantly impact the way we treat breast cancer. It will feature phase 3 data with novel SERDs, novel ADCs, immunotherapy, ctDNA monitoring, important biomarker analyses & so much more. Here’s my top 10 abstracts list— see you in San Antonio!

Finally made the move! Send any #medonc and #medtwitter starter packs my way 🙏🏻